Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis

Int Ophthalmol. 2018 Apr;38(2):781-785. doi: 10.1007/s10792-017-0502-x. Epub 2017 Mar 30.


Purpose: To report a case of juxtafoveal choroidal neovascularization in a patient with candida chorioretinitis successfully treated with intravitreal bevacizumab.

Methods: Case report.

Results: A 45-year-old woman previously treated for candida chorioretinitis was presented with reduced vision in the left eye. The patient was investigated with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT). Following initial treatment, fundus examination, fluorescein angiography, and OCT of the right eye revealed a secondary juxtafoveal classic choroidal neovascularization. Following a single intravitreal injection of bevacizumab, the patient had excellent visual recovery, with absence of subretinal or intraretinal fluid in the OCT.

Conclusions: Bevacizumab was effective in treatment of choroidal neovascularization associated with candida chorioretinitis.

Keywords: Bevacizumab; Candida; Chorioretinitis; Choroidal neovascular membrane.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Candidiasis / complications*
  • Chorioretinitis / etiology*
  • Choroidal Neovascularization / drug therapy*
  • Eye Infections, Fungal / complications*
  • Female
  • Humans
  • Middle Aged
  • Treatment Outcome


  • Angiogenesis Inhibitors
  • Bevacizumab